ATE516497T1 - Screening für funktionshomologien - Google Patents

Screening für funktionshomologien

Info

Publication number
ATE516497T1
ATE516497T1 AT01914718T AT01914718T ATE516497T1 AT E516497 T1 ATE516497 T1 AT E516497T1 AT 01914718 T AT01914718 T AT 01914718T AT 01914718 T AT01914718 T AT 01914718T AT E516497 T1 ATE516497 T1 AT E516497T1
Authority
AT
Austria
Prior art keywords
screening
pathways
analysis
identification
rapid identification
Prior art date
Application number
AT01914718T
Other languages
English (en)
Inventor
Ellen Berg
Eugene Butcher
Jennifer Melrose
Ivan Plavec
Original Assignee
Asterand Acquisition Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterand Acquisition Llc filed Critical Asterand Acquisition Llc
Application granted granted Critical
Publication of ATE516497T1 publication Critical patent/ATE516497T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06—Quantitative determination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N5/00—Analysing materials by weighing, e.g. weighing small particles separated from a gas or liquid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Treatment Of Sludge (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01914718T 2000-03-06 2001-03-06 Screening für funktionshomologien ATE516497T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18697600P 2000-03-06 2000-03-06
US19567200P 2000-04-07 2000-04-07
PCT/US2001/007190 WO2001067103A1 (en) 2000-03-06 2001-03-06 Function homology screening

Publications (1)

Publication Number Publication Date
ATE516497T1 true ATE516497T1 (de) 2011-07-15

Family

ID=26882614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01914718T ATE516497T1 (de) 2000-03-06 2001-03-06 Screening für funktionshomologien

Country Status (7)

Country Link
US (6) US6656695B2 (de)
EP (1) EP1269187B8 (de)
JP (1) JP4798921B2 (de)
AT (1) ATE516497T1 (de)
AU (2) AU4007401A (de)
CA (1) CA2400989C (de)
WO (1) WO2001067103A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050221280A1 (en) * 1998-02-02 2005-10-06 Odyssey Thera, Inc. Protein-protein interactions for pharmacological profiling
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
WO2001067103A1 (en) * 2000-03-06 2001-09-13 Bioseek, Inc. Function homology screening
US7521192B2 (en) * 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7381535B2 (en) * 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
AU2002365421A1 (en) * 2001-07-10 2003-09-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of the multiple proteins in single cells
EP1425695A2 (de) * 2001-08-13 2004-06-09 Beyong Genomics, Inc. Verfahren und system zum profilieren von biologischen systemen
US20050170372A1 (en) * 2001-08-13 2005-08-04 Afeyan Noubar B. Methods and systems for profiling biological systems
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2004094992A2 (en) * 2003-04-23 2004-11-04 Bioseek, Inc. Methods for analysis of biological dataset profiles
WO2004094609A2 (en) * 2003-04-23 2004-11-04 Bioseek, Inc. Methods for characterizing signaling pathways and compounds that interact therewith
AU2004271183A1 (en) * 2003-09-03 2005-03-17 Bioseek, Inc. Cell-based assays for determining drug action
EP1664796B1 (de) * 2003-09-15 2010-12-15 Oklahoma Medical Research Foundation Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
US20050142608A1 (en) * 2003-09-22 2005-06-30 Yokogawa Electric Corporation Screening method and device, and new drug screening method and device
CA2597409A1 (en) * 2004-02-27 2005-10-06 Bioseek, Inc. Biological dataset profiling of asthma and atopy
US7374536B1 (en) 2004-04-16 2008-05-20 Taylor Colin R Method for analysis of pain images
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
WO2006060335A2 (en) * 2004-11-30 2006-06-08 Cell Networx Llc Cellular signaling pathway based assays, reagents and kits
JP2008528975A (ja) * 2005-01-24 2008-07-31 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 細胞シグナル伝達系のモデリングのためのベイジアンネットワークの使用
AU2006216514C1 (en) * 2005-02-25 2012-09-27 Isis Pharmaceuticals, Inc. Compositions and their uses directed to IL-4R alpha
EP1872293A4 (de) * 2005-03-28 2010-01-06 Bioseek Inc Profilierung biologischer datensätze für kardiovaskuläre erkrankungen und kardiovaskuläre entzündungen
WO2006104201A1 (ja) * 2005-03-29 2006-10-05 Olympus Corporation 細胞画像解析方法、細胞画像解析プログラム、細胞画像解析装置、スクリーニング方法およびスクリーニング装置
US8426146B2 (en) 2005-06-03 2013-04-23 University of Pittsburgh—of the Commonwealth System of Higher Education Multiparameteric method for assessing immune system status
EP1922332A2 (de) * 2005-09-09 2008-05-21 The University Of Chicago Verfahren und zusammensetzungen zur diagnose und immuntherapie von pollenallergie
JP2009510174A (ja) * 2005-10-03 2009-03-12 アイシス ファーマシューティカルズ， インコーポレーテッド ブデソニドおよびｉｌ−４受容体アルファを標的化するアンチセンスオリゴヌクレオチドを用いた併用療法
US20070270366A1 (en) * 2005-12-20 2007-11-22 Karras James G Double stranded nucleic acid molecules targeted to il-4 receptor alpha
US20090170091A1 (en) * 2006-01-17 2009-07-02 Kenneth Giuliano Method For Predicting Biological Systems Responses
US20080051335A1 (en) * 2006-05-02 2008-02-28 Kleiner Lothar W Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers
US8114615B2 (en) 2006-05-17 2012-02-14 Cernostics, Inc. Method for automated tissue analysis
US8697387B2 (en) * 2006-06-02 2014-04-15 DiscoverRx Corporation Methods for identifying agents and their use for the prevention of restenosis
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8048448B2 (en) * 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US20100093613A1 (en) * 2007-03-09 2010-04-15 Kunkel Eric J Methods for identifying agents and their use for the prevention or stabilization of fibrosis
EP2152944A4 (de) * 2007-03-30 2010-12-01 Bioseek Inc Verfahren zur klassifizierung toxischer mittel und gegenmittel
US20090099784A1 (en) * 2007-09-26 2009-04-16 Ladd William M Software assisted methods for probing the biochemical basis of biological states
GB0800938D0 (en) 2008-01-18 2008-02-27 Ge Healthcare Uk Ltd Multiplex cell signalling assay
WO2009134944A2 (en) * 2008-04-29 2009-11-05 Nodality, Inc. Methods of determining the health status of an individual
US20090291458A1 (en) * 2008-05-22 2009-11-26 Nodality, Inc. Method for Determining the Status of an Individual
US8227202B2 (en) * 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20100099109A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc., A Delaware Corporation Methods for Analyzing Drug Response
GB0908788D0 (en) * 2009-05-21 2009-07-01 Univ Southampton Tissue analysis
US8765370B2 (en) * 2009-06-11 2014-07-01 Scinopharm Taiwan, Ltd Inhibition-based high-throughput screen strategy for cell clones
GB0916585D0 (en) * 2009-09-21 2009-10-28 Plasticell Ltd Apparatus and method for processing cell culture data
US20120034613A1 (en) * 2010-08-03 2012-02-09 Nse Products, Inc. Apparatus and Method for Testing Relationships Between Gene Expression and Physical Appearance of Skin
US10018631B2 (en) 2011-03-17 2018-07-10 Cernostics, Inc. Systems and compositions for diagnosing Barrett's esophagus and methods of using the same
EP3014268B1 (de) * 2013-06-26 2020-08-05 Valitacell Limited Verfahren mit hohem durchlauf zum schnellen vorhersagen der relativen zulaufleistung einer tafel von per klonung von einer wirtszellenpopulation abgeleiteten zellen
WO2015109003A1 (en) * 2014-01-14 2015-07-23 Asedasciences Ag Identification of functional cell states
GB201511419D0 (en) * 2015-06-30 2015-08-12 Ge Healthcare Uk Ltd The use of bioinformatic data in autolobous cell therapies
CN108763864B (zh) * 2018-05-04 2021-06-29 温州大学 一种评价生物通路样本状态的方法
CN114258317B (zh) * 2019-06-18 2025-03-14 斯克里普斯研究学院 用于治疗炎性病症的方法和组合物
US11600388B2 (en) 2019-08-19 2023-03-07 MediSync Inc. Artificial intelligence systems that incorporate expert knowledge related to hypertension treatments
EP4301378A4 (de) * 2021-03-03 2025-02-12 Georgia Tech Research Corporation Zellkulturwachstumsvorrichtung und verfahren zur unterseitigen befestigung an einer oberfläche mittels zellenaussaat
US20240337647A1 (en) 2021-07-26 2024-10-10 Asedasciences Ag Improved methods for identification of functional cell states
EP4431090A1 (de) 2023-03-15 2024-09-18 Istesso 1 Limited Solfonamide als mitochondriale komplex-i-modulator-verbindungen
GB202308547D0 (en) 2023-06-08 2023-07-26 Istesso 2 Ltd Tnf inhibitor combination therapies
GB202309515D0 (en) 2023-06-23 2023-08-09 Istesso 2 Ltd JAK inhibitor and IL-6 inhibitor combination therapies
GB202315822D0 (en) 2023-10-16 2023-11-29 Istesso 3 Ltd Anti-fibrotic combination therapeutics
GB202317050D0 (en) 2023-11-07 2023-12-20 Istesso 2 Ltd Disease modifying anti-rheumatic drug combination therapies
US12401829B1 (en) * 2024-04-05 2025-08-26 Sharp Kabushiki Kaisha Systems and methods for performing motion compensation for bi-prediction in video coding
GB202411554D0 (en) 2024-08-06 2024-09-18 Istesso 2 Ltd NF-kB inhibitor combination therapies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
AU621972B2 (en) * 1988-12-14 1992-03-26 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Cell culture medium for human liver epithelial cell line
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5665553A (en) * 1993-04-30 1997-09-09 Pacific Northwest Research Foundation Methods for determining and modulating cellular redox potential and genotoxic states
DK0650396T3 (da) * 1993-05-17 1998-09-14 Amersham Int Plc Udstyr og fremgangsmåde til måling af celluære biokemiske processer.
WO1995006132A2 (en) * 1993-08-27 1995-03-02 Myco Pharmaceuticals, Incorporated Identifying biologically active agents through culture color change
EP0805872A1 (de) 1995-01-23 1997-11-12 Microcide Pharmaceuticals, Inc. Methode zum screenen von modulators von biomolekulen
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5777888A (en) 1995-08-09 1998-07-07 Regents Of The University Of California Systems for generating and analyzing stimulus-response output signal matrices
US6013437A (en) 1996-11-12 2000-01-11 Qbi Enterprises, Ltd. Method for identifying translationally regulated genes
US5981472A (en) * 1997-02-21 1999-11-09 Dx/Ibr Corporation Methods for treating diseases
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US5965352A (en) * 1998-05-08 1999-10-12 Rosetta Inpharmatics, Inc. Methods for identifying pathways of drug action
US6518035B1 (en) * 1998-06-02 2003-02-11 Rosetta Inpharmatics, Inc. Targeted methods of drug screening using co-culture methods
US6146830A (en) 1998-09-23 2000-11-14 Rosetta Inpharmatics, Inc. Method for determining the presence of a number of primary targets of a drug
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
US6801859B1 (en) * 1998-12-23 2004-10-05 Rosetta Inpharmatics Llc Methods of characterizing drug activities using consensus profiles
JP2002537793A (ja) 1999-03-02 2002-11-12 ザ ユニヴァーシティー オブ ダンディー 変更したＮＤＰＫ機能を決定する方法及び嚢胞性線維症の診断法（ｄｉａｇｎｏｓｉｓ）
WO2001051664A2 (en) 2000-01-12 2001-07-19 Dana-Farber Cancer Institute, Inc. Method of detecting and characterizing a neoplasm
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
WO2001067103A1 (en) * 2000-03-06 2001-09-13 Bioseek, Inc. Function homology screening
US7266458B2 (en) 2000-03-06 2007-09-04 Bioseek, Inc. BioMAP analysis
EP1221618A1 (de) 2000-11-29 2002-07-10 GeneScan Europe AG Diagnoseverfahren für allergische Erkrankungen
EP2152944A4 (de) * 2007-03-30 2010-12-01 Bioseek Inc Verfahren zur klassifizierung toxischer mittel und gegenmittel

Also Published As

Publication number Publication date
CA2400989A1 (en) 2001-09-13
WO2001067103A9 (en) 2002-12-27
JP2003527110A (ja) 2003-09-16
EP1269187A4 (de) 2005-11-09
US20030113807A1 (en) 2003-06-19
US20080070271A1 (en) 2008-03-20
US20080064056A1 (en) 2008-03-13
US20040157269A1 (en) 2004-08-12
AU4007401A (en) 2001-09-17
AU2001240074B2 (en) 2006-02-23
EP1269187A1 (de) 2003-01-02
CA2400989C (en) 2014-09-30
US20040063088A1 (en) 2004-04-01
WO2001067103A1 (en) 2001-09-13
JP4798921B2 (ja) 2011-10-19
US20130266967A1 (en) 2013-10-10
US8467970B2 (en) 2013-06-18
EP1269187B1 (de) 2011-07-13
US6656695B2 (en) 2003-12-02
US7912651B2 (en) 2011-03-22
US10018621B2 (en) 2018-07-10
EP1269187B8 (de) 2011-10-05

Similar Documents

Publication Publication Date Title
ATE516497T1 (de) Screening für funktionshomologien
DE69738996D1 (de) Miniaturisierte zellenanordnung und verfahren und vorrichtung zum screening mittels zellen
ATE346156T1 (de) Umkehrtransfektionsverfahren
WO2004055519A3 (en) Specific markers for pancreatic cancer
ATE389008T1 (de) Verfahren und vorrichtung zum züchten und/oder behandeln von zellen
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
ATE515575T1 (de) Verfahren und sonden für den nachweis von krebs
DE60233574D1 (de) Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
DE69822206D1 (de) Erkenntnisse der genomforschung für die suche nach neuartigen wirkstoffen
ATE295899T1 (de) Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten
PL354423A1 (en) Method of biological fluid sampling and making corresponding analyte measurements as well as an electrochemical cell, apparatus and system therefor
DK1032705T3 (da) Probearrays og fremgangsmåder til at benytte probearrays til at skelne mellem DNA
DE60029369D1 (de) Verfahren und Sondenset zur Erkennung von Krebs
ATE490466T1 (de) Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen
GB2385053A (en) Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human breast and HBL 100 cells
DE60040335D1 (de) Derivatisierte nukleinsäuren und deren verwendung
DE69941044D1 (de) Methoden, Apparat und Computerprogramm zur quantitativen Bestimmung von Nukleinsäurensequenzen in Proben unter Verwendung von Standardkurven und Abschätzungen von Amplifikationsverhältnissen
DE69632252D1 (de) Verfahren zur erkennung von klonalen populationen von transformierten zellen in einer genomisch heterogenen zellulären probe
ATE239274T1 (de) Proteom-analyse zum charakterisieren von auf- und abgeregelten proteinen in biologischen proben
DE69940753D1 (de) Verfahren zur Einführung von heterologischen Zellen in Fische
WO2002066975A3 (en) Tissue-based water quality biosensors for detecting chemical warfare agents
ATE508201T1 (de) Verfahren zur generierung eines gentechnisch veränderten organismus für das wirksubstanzscreening
WO2004013603A3 (en) A method of sample preparation for atom probes and source of specimens
FI20040255A7 (fi) Menetelmä pre-eklampsian riskin havaitsemiseksi
WO2003095624A3 (en) Liver inflammation predictive genes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties